Priv. Doz. OA Dr.
Alexander EglePriv. Doz. OA Dr. Alexander Egle

Verantwortlicher Oberarzt

Okt 2013

Kongresssekretär der Gemeinsamen Jahrestagung der Österreichischen, Deutschen und Schweizer Gesellschaften für Hämatologie und Onkologie

 

Seit Apr 2010

Mitglied des wissenschaftlichen Komitees des Wissenschaftsfonds der Paracelsus Medizinischen Privatuniversität Salzburg

 

April 2009

Kongresssekretär der Frühjahrstagung der Österreichischen Gesellschaft für Hämatologie und Onkologie

 

Seit Nov 2006

Entwicklung und Management des klinischen GMP Stammzelllabors der III. medizinischen Abteilung der Salzburger Landeskliniken

 

Seit Feb 2006

Habilitation an der Paracelsus Medizinischen Privatuniversität Salzburg

 

Seit Sept 2005

Leiter der Infektiologischen Ambulanz der III. medizinischen Abteilung der Salzburger Landeskliniken


Jan 2005

Beginn der Lehrtätigkeit an der Paracelsus Medizinischen Privatuniversität Salzburg und Einreichung der Habilitationsschrift

 

Seit Nov 2004

Leiter der Laborgruppe für die Entwicklung muriner Lymphom Modelle

 

Seit Jan 2004

Leitung der Hämatologischen Ambulanz der III. Medizinischen Klinik der Salzburger Landeskliniken

 

Apr 2003 - Dez 2003

Rückkehr in das Facharztausbildungsprogramm der Klinik Innsbruck – Ernennung zum Facharzt für Innere Medizin

 

Nov 2002 - Mär 2003

Senior research officer level 5b am Walter and Eliza Hall Institut in Melbourne, Australien (Finanzierung durch NCI grant CA43540 und Leukemia and Lymphoma Society SCOR grant 7015)

 

Nov 2000 - Nov 2002

Erwin-Schrödinger Stipendiat des Österreichischen Wissenschaftsfonds FWF am Walter and Eliza Hall Institute of Medical Research unter der Führung von Prof. Suzanne Cory in der Abteilung für Molekulare Genetik von Krebs (Nummern J2129/J1921)

 

Aug 1996

Beginn der klinischen Ausbildung zum Facharzt für Innere Medizin an der Universitätsklinik für Innere Medizin Innsbruck

 

1993 - 2000

Postdoc-Stelle im Molekularzytologischen Labor der Universitätsklinik für Innere Medizin Innsbruck unter der Leitung von Prof Dr. Greil Richard

 

Jun 1993

Promotion zum Dr. med. an der Universität Innsbruck

 

1990 - 1993

Dissertation zum Thema "Zytostatische Wirkung von Inhibitoren der Protein Kinase C" am Institut für klinische Chemie und Biochemie an der Universität Innsbruck (Betreuer: Univ. Prof. Dr. H.H. Grunicke)

 

1987 - 1993

Medizinstudium an der Leopold Franzens Universität in Innsbruck

 

 

Forschungsförderungen

 

Ad personam

Univ. Innsbruck Forschungsstipendium

Hans and Blanca Moser Foundation

Erwin Schrödinger Stipendium des österreichischen FWF (Projekt J1921 und Folgeprojekt J2129)

Österreichische Nationalbank Projekt Number 10990

Forschungsförderung von Celgene Intl

Forschungsförderung der Paracelsus medizinischen Privatuniversität Salzburg in den Jahren 2010, 2011, 2012, 2013 und 2014 (laufend) Translationale Forschungsförderung durch den FWF (L488)

Mitantragsteller und Mentor im Firnberg-Programm des FWF (T671, laufend)

Internationale Forschungsförderung durch den FWF (I 1299, laufend)

Einzelprojektförderungen durch den FWF (P19481 - abgeschlossen und P26719 - laufend)

 

 

Beitrag

Österreichische Nationalbank


Eli Lilly Stiftung


US NCI (grant CA43540)


Leukemia and Lymphoma Society SCOR grant 7015


NHMRC (Canberra) program grant 257502

 

 

Auszeichnungen / Vorträge

 

Erstautor


Dissertationspreis der Hans und Blanca Moser Stiftung und der Stadt Dornbirn


Posterpreis der Österreichischen Gesellschaft für Hämatologie und Onkologie 1997


Auswahl als bester Abstract bei der Frühjahrstagung der Österreichischen Gesellschaft für Hämatologie und Onkologie 2003, Dornbirn mit Plenarvortrag


Auswahl als bester Abstract im Rahmen der Postersitzung der Österreichischen Gesellschaft für Hämatologie und Onkologie


Zahlreiche Vorträge bei nationalen und internationalen Kongressen unter anderem bei Tagungen der Deutschen/Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkolgie, der Deutschen CLL Studiengruppe und der Amerikanischen Gesellschaft für Hämatologie (ASH) Wissenschaftsmedaillen der Paracelsus Medizinischen Privatuniversität seit 2009

 

 

Koautor


AVENTIS Preis 1998 (Erstautor: Dr. Andreas Villunger)


AVENTIS Preis 1999 (Erstautor: Dr. Ingeborg Tinhofer)

Hoechst Preis 1998 (Erstautor: Dr. Andreas Villunger)

Hoechst Preis 1999 (Erstautor: Dr. Ingeborg Tinhofer)

Denk Preis 2000 (Erstautor: Dr. Ingeborg Tinhofer)

Türk Preis 2010 (Erstautor: Dr. Daniela Asslaber)

Sanofi Aventis Preis 2010 (Erstautor: Dr. Daniela Asslaber)

Sanofi Aventis Preis 2012 (Erstautor: Dr. Josefina Pinon-Hofbauer)

 

Review-Tätigkeit

 

Abstract Gutachter für mehrere ASH Meetings

Gutachter der Österreischen Nationalbank

Gutachter Cancer Research, UK

 

Journale:

Cell Death and Differentiation


Blood

Leukemia

PNAS

BMC Cancer

PLOS One

Bioassays

Annals Hematology

Cancer Research

Oncogene

  • 2017

    Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience.

    Leisch, M, Weiss, L, Lindlbauer, N, Jungbauer, C, Egle, A, Rohde, E, Greil, R, Grabmer, C, Pleyer, L.
    Leuk Res. 2017, 59:12-19.

    View this publication in the PUBMED database
  • 2017

    Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.

    Magnes, T, Melchardt, T, Weiss, L, Mittermair, C, Neureiter, D, Klieser, E, Gampenrieder, S, Moser, G, Gaggl, A, Greil, R, Egle, A.
    PLoS One. 2017, 12(7):e0180995.

    View this publication in the PUBMED database
  • 2017

    The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.

    Magnes, T, Melchardt, T, Hufnagl, C, Weiss, L, Mittermair, C, Neureiter, D, Klieser, E, Rinnerthaler, G, Roesch, S, Gaggl, A, Greil, R, Egle, A.
    Pharmacogenomics J. 2017.

    View this publication in the PUBMED database
  • 2017

    Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.

    Kazianka, L, Drucker, C, Skrabs, C, Thomas, W, Melchardt, T, Struve, S, Bergmann, M, Staber, PB, Porpaczy, E, Einberger, C, Heinz, M, Hauswirth, A, Raderer, M, Pabinger, I, Thalhammer, R, Egle, A, Wendtner, CM, Follows, G, Hoermann, G, Quehenberger, P, Jilma, B, Jaeger, U.
    Leukemia. 2017, 31(5):1117-1122.

    View this publication in the PUBMED database
  • 2017

    Milestones in Chronic Lymphocytic Leukemia: An exciting decade of progress-10th anniversary of memo.

    Egle, A.
    Memo. 2017, 10(1):8-12.

    View this publication in the PUBMED database
  • 2017

    Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial.

    Weiss, L, Melchardt, T, Egle, A, Hopfinger, G, Hackl, H, Greil, R, Barth, J, Rummel, M.
    Ann Hematol. 2017.

    View this publication in the PUBMED database
  • 2017

    A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

    Kiesewetter, B, Willenbacher, E, Willenbacher, W, Egle, A, Neumeister, P, Voskova, D, Mayerhoefer, ME, Simonitsch-Klupp, I, Melchardt, T, Greil, R, Raderer, M.
    Blood. 2017, 129(3):383-385

    View this publication in the PUBMED database
  • 2016

    Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

    Greil, R, Obrtlíková, P, Smolej, L, Kozák, T, Steurer, M, Andel, J, Burgstaller, S, Mikušková, E, Gercheva, L, Nösslinger, T, Papajík, T, Ladická, M, Girschikofsky, M, Hrubiško, M, Jäger, U, Fridrik, M, Pecherstorfer, M, Králiková, E, Burcoveanu, C, Spasov, E, Petzer, A, Mihaylov, G, Raynov, J, Oexle, H, Zabernigg, A, Flochová, E, Palášthy, S, Stehlíková, O, Doubek, M, Altenhofer, P, Pleyer, L, Melchardt, T, Klingler, A, Mayer, J, Egle, A.
    Lancet Haematol. 2016, 3(7): e317-e329.

    View this publication in the PUBMED database
  • 2016

    Bcl-2 proteins in development, health, and disease of the hematopoietic system.

    Kollek, M, Müller, A, Egle, A, Erlacher, M.
    FEBS J. 2016, 283(15): 2779-2810.

    View this publication in the PUBMED database
  • 2016

    Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones.

    Melchardt, T, Hufnagl, C, Weinstock, DM, Kopp, N, Neureiter, D, Tränkenschuh, W, Hackl, H, Weiss, L, Rinnerthaler, G, Hartmann, TN, Greil, R, Weigert, O, Egle, A.
    Oncotarget. 2016, xx:

    View this publication in the PUBMED database
  • 2016

    NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.

    Prochazka, KT, Melchardt, T, Posch, F, Schlick, K, Deutsch, A, Beham-Schmid, C, Weiss, L, Gary, T, Neureiter, D, Klieser, E, Greil, R, Neumeister, P, Egle, A, Pichler, M.
    Br J Cancer. 2016, xx:

    View this publication in the PUBMED database
  • 2016

    Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping.

    Magnes, T, Melchardt, T, Weiss, L, Hufnagl, C, Greil, R, Egle, A.
    J Clin Oncol. 2016, 34(20): 2433-2434.

    View this publication in the PUBMED database
  • 2016

    Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.

    Huemer, F, Dejaco, M, Grabmer, C, Melchardt, T, Neureiter, D, Mayer, G, Egle, A, Greil, R, Weiss, L.
    Wien Klin Wochenschr. 2016,

    View this publication in the PUBMED database
  • 2016

    Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?.

    Zaborsky, N, Gassner, FJ, Asslaber, D, Reinthaler, P, Denk, U, Flenady, S, Hofbauer, JP, Danner, B, Rebhandl, S, Harrer, A, Geisberger, R, Greil, R, Egle, A.
    Oncotarget. 2016,

    View this publication in the PUBMED database
  • 2016

    An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide?+?dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).

    Kollek, M, Müller, A, Egle, A, Erlacher, M.
    FEBS J. 2016, 283(15):2779-2810

    View this publication in the PUBMED database
  • 2016

    Developing a cancer immunogene therapy approach for Epidermolysis bullosa-associated squamous cell carcinoma.

    Melchardt, T, Hufnagl, C, Weinstock, DM, Kopp, N, Neureiter, D, Tränkenschuh, W, Hackl, H, Weiss, L, Rinnerthaler, G, Hartmann, TN, Greil, R, Weigert, O, Egle, A.
    Oncotarget. 2016,

    View this publication in the PUBMED database
  • 2016

    CRISPR/Cas9-mediated gene repair in the COL7A1 gene.

    Prochazka, KT, Melchardt, T, Posch, F, Schlick, K, Deutsch, A, Beham-Schmid, C, Weiss, L, Gary, T, Neureiter, D, Klieser, E, Greil, R, Neumeister, P, Egle, A, Pichler, M.
    Br J Cancer. 2016,

    View this publication in the PUBMED database
  • 2016

    Bcl-2 proteins in development, health, and disease of the hematopoietic system.

    Kollek, M, Müller, A, Egle, A, Erlacher, M.
    FEBS J. 2016, 283(15):2779-2810

    View this publication in the PUBMED database
  • 2016

    CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells.

    Zaborsky, N, Gassner, FJ, Asslaber, D, Reinthaler, P, Denk, U, Flenady, S, Hofbauer, JP, Danner, B, Rebhandl, S, Harrer, A, Geisberger, R, Greil, R, Egle, A.
    Oncotarget. 2016,

    View this publication in the PUBMED database
  • 2016

    Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping.

    Magnes, T, Melchardt, T, Weiss, L, Hufnagl, C, Greil, R, Egle, A.
    J Clin Oncol. 2016, 34(20):2433-2434

    View this publication in the PUBMED database
  • 2016

    Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.

    Hanna, BS, McClanahan, F, Yazdanparast, H, Zaborsky, N, Kalter, V, Rößner, PM, Benner, A, Dürr, C, Egle, A, Gribben, JG, Lichter, P, Seiffert, M.
    Leukemia. 2016, 30(3): 570-579.

    View this publication in the PUBMED database
  • 2016

    The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma.

    Troppan, KT, Melchardt, T, Wenzl, K, Schlick, K, Deutsch, A, Bullock, MD, Reitz, D, Beham-Schmid, C, Weiss, L, Neureiter, D, Tränkenschuh, W, Greil, R, Neumeister, P, Egle, A, Pichler, M.
    J Clin Pathol. 2016, 69(4):326-330.

    View this publication in the PUBMED database
  • 2016

    ILK Induction in Lymphoid Organs by a TNFα-NF-κB-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia.

    Krenn, PW, Hofbauer, SW, Pucher, S, Hutterer, E, Hinterseer, E, Denk, U, Asslaber, D, Ganghammer, S, Sternberg, C, Neureiter, D, Aberger, F, Wickström, SA, Egle, A, Greil, R, Hartmann, TN.
    Cancer Res. 2016, 76(8):2186-2196.

    View this publication in the PUBMED database
  • 2016

    The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells.

    Hofbauer, SW, Krenn, PW, Piñόn Hofbauer, J, Pucher, S, Asslaber, D, Egle, A, Hartmann, TN, Greil, R.
    Br J Haematol. 2016, 172(5): 815-819.

    View this publication in the PUBMED database
  • 2016

    A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

    "Rawstron, AC, Fazi, C, Agathangelidis, A, Villamor, N, Letestu, R, Nomdedeu, J, Palacio, C, Stehlikova, O, Kreuzer, KA, Liptrot, S, O""Brien, D, de Tute, RM, Marinov, I, Hauwel, M, Spacek, M, Dobber, J, Kater, AP, Gambell, P, Soosapilla, A, Lozanski, G, Brachtl, G, Lin, K, Boysen, J, Hanson, C, Jorgensen, JL, Stetler-Stevenson, M, Yuan, C, Broome, HE, Rassenti, L, Craig, F, Delgado, J, Moreno, C, Bosch, F, Egle, A, Doubek, M, Pospisilova, S, Mulligan, S, Westerman, D, Sanders, CM, Emerson, R, Robins, HS, Kirsch, I, Shanafelt, T, Pettitt, A.Kipps, TJ, Wierda, WG, Cymbalista, F, Hallek, M, Hillmen, P, Montserrat, E, Ghia, P."
    Leukemia. 2016, 30(4):929-936.

    View this publication in the PUBMED database
  • 2016

    Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones.

    Melchardt, T, Hufnagl, C, Weinstock, DM, Kopp, N, Neureiter, D, Tränkenschuh, W, Hackl, H, Weiss, L, Rinnerthaler, G, Hartmann, TN, Greil, R, Weigert, O, Egle, A.
    Oncotarget. 2016.

    View this publication in the PUBMED database
  • 2015

    The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.

    Troppan, KT, Melchardt, T, Deutsch, A, Schlick, K, Stojakovic, T, Bullock, MD, Reitz, D, Beham-Schmid, C, Weiss, L, Neureiter, D, Wenzl, K, Greil, R, Neumeister, P, Egle, A, Pichler, M.
    Eur J Haematol. 2015, 95(6): 538-544.

    View this publication in the PUBMED database
  • 2015

    CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model.

    Kocher, T, Asslaber, D, Zaborsky, N, Flenady, S, Denk, U, Reinthaler, P, Ablinger, M, Geisberger, R, Bauer, JW, Seiffert, M, Hartmann, TN, Greil, R, Egle, A, Hofbauer, JP.
    Leukemia. 2015, xx.

    View this publication in the PUBMED database
  • 2015

    Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy.

    Sochalska, M, Tuzlak, S, Egle, A, Villunger, A.
    FEBS J. 2015, 282(5): 834-849.

    View this publication in the PUBMED database
  • 2015

    A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2 -microglobulin.

    Melchardt, T, Troppan, K, Weiss, L, Hufnagl, C, Neureiter, D, Tränkenschuh, W, Hopfinger, G, Magnes, T, Deutsch, A, Neumeister, P, Hackl, H, Greil, R, Pichler, M, Egle, A.
    Br J Haematol. 2015, 168(2):239-245.

    View this publication in the PUBMED database
  • 2015

    Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.

    Melchardt, T, Weiss, L, Hufnagl, C, Neureiter, D, Kemmerling, R, Morre, P, Boekstegers, A, Hopfinger, G, Auberger, J, Steinkirchner, S, Pleyer, L, Greil, R, Egle, A.
    Leuk Lymphoma. 2015, 56(2):353-360.

    View this publication in the PUBMED database
  • 2015

    Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.

    Them, NC, Bagienski, K, Berg, T, Gisslinger, B, Schalling, M, Chen, D, Buxhofer-Ausch, V, Thaler, J, Schloegl, E, Gastl, GA, Wolf, D, Strecker, K, Egle, A, Melchardt, T, Burgstaller, S, Willenbacher, E, Zagrijtschuk, O, Klade, C, Greil, R, Gisslinger, H, Kralovics, R.
    Am J Hematol. 2015, 90(4): 288-294.

    View this publication in the PUBMED database
  • 2015

    B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia.

    Zaborsky, N, Holler, C, Geisberger, R, Asslaber, D, Gassner, FJ, Egger, V, Piñón-Hofbauer, J, Kocher, T, Hartmann, TN, Greil, R, Egle, A.
    Haematologica. 2015, 100(8): e307-e310.

    View this publication in the PUBMED database
  • 2015

    Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.

    Gassner FJ, Zaborsky N, Catakovic K, Rebhandl S, Huemer M, Egle A, Hartmann TN, Greil R, Geisberger R.
    Br J Haematol. 2015 Aug,170(4):515-22. doi: 10.1111/bjh.13467. Epub 2015 May 4.

    View this publication in the PUBMED database
  • 2015

    Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

    Gnant, M, Pfeiler, G, Dubsky, PC, Hubalek, M, Greil, R, Jakesz, R, Wette, V, Balic, M, Haslbauer, F, Melbinger, E, Bjelic-Radisic, V, Artner-Matuschek, S, Fitzal, F, Marth, C, Sevelda, P, Mlineritsch, B, Steger, GG, Manfreda, D, Exner, R, Egle, D, Bergh, J, Kainberger, F, Talbot, S, Warner, D, Fesl, C, Singer, CF.
    LANCET. 2015, 386(9992): 433-443.

    View this publication in the PUBMED database
  • 2015

    CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.

    Ganghammer, S, Hutterer, E, Hinterseer, E, Brachtl, G, Asslaber, D, Krenn, PW, Girbl, T, Berghammer, P, Geisberger, R, Egle, A, Zucchetto, A, Kruschinski, A, Gattei, V, Chigaev, A, Greil, R, Hartmann, TN.
    Oncotarget. 2015, 6(14): 12048-12060.

    View this publication in the PUBMED database
  • 2015

    CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.

    Melchardt, T, Hufnagl, C, Magnes, T, Weiss, L, Hutarew, G, Neureiter, D, Schlattau, A, Moser, G, Gaggl, A, Tränkenschuh, W, Greil, R, Egle, A.
    BMC Cancer. 2015, 15:725

    View this publication in the PUBMED database
  • 2015

    Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI.

    Melchardt, T, Troppan, K, Weiss, L, Hufnagl, C, Neureiter, D, Tränkenschuh, W, Schlick, K, Huemer, F, Deutsch, A, Neumeister, P, Greil, R, Pichler, M, Egle, A.
    J Natl Compr Canc Netw. 2015, 13(12):1501-1508

    View this publication in the PUBMED database
  • 2015

    Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.

    Gisslinger, H, Zagrijtschuk, O, Buxhofer-Ausch, V, Thaler, J, Schloegl, E, Gastl, GA, Wolf, D, Kralovics, R, Gisslinger, B, Strecker, K, Egle, A, Melchardt, T, Burgstaller, S, Willenbacher, E, Schalling, M, Them, NC, Kadlecova, P, Klade, C, Greil, R.
    Blood. 2015, 126(15): 1762-1769.

    View this publication in the PUBMED database
  • 2015

    Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer.

    Huemer, F, Melchardt, T, Tränkenschuh, W, Neureiter, D, Moser, G, Magnes, T, Weiss, L, Schlattau, A, Hufnagl, C, Ricken, G, Höftberger, R, Greil, R, Egle, A.
    BMC Cancer. 2015, 15:996

    View this publication in the PUBMED database
  • 2014

    Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.

    Gassner FJ, Zaborsky N, Neureiter D, Huemer M, Melchardt T, Egle A, Rebhandl S, Catakovic K, Hartmann TN, Greil R, Geisberger R.
    Haematologica. 2014 May,99(5):67-9. doi: 10.3324/haematol.2013.098459. Epub 2014 Feb 21.

    View this publication in the PUBMED database
  • 2014

    Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade.

    Grössinger EM, Weiss L, Zierler S, Rebhandl S, Krenn PW, Hinterseer E, Schmölzer J, Asslaber D, Hainzl S, Neureiter D, Egle A, Piñón-Hofbauer J, Hartmann TN, Greil R, Kerschbaum HH.
    Leukemia. 2014 Apr,28(4):954-8. doi: 10.1038/leu.2014.37. Epub 2014 Jan 20.

    View this publication in the PUBMED database
  • 2014

    Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.

    Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Zagrijtschuk O, Klade C, Greil R, Gisslinger H, Kralovics R.
    Am J Hematol. 2015 Apr,90(4):288-94. doi: 10.1002/ajh.23928. Epub 2015 Mar 2.

    View this publication in the PUBMED database
  • 2014

    A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β(2) -microglobulin.

    Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Tränkenschuh W, Hopfinger G, Magnes T, Deutsch A, Neumeister P, Hackl H, Greil R, Pichler M, Egle A.
    Br J Haematol. 2015 Jan,168(2):239-45. doi: 10.1111/bjh.13116. Epub 2014 Sep 19.

    View this publication in the PUBMED database
  • 2014

    Kasabach-Merritt phenomenon in hepatic angiosarcoma.

    Habringer S, Boekstegers A, Weiss L, Hopfinger G, Meissnitzer T, Melchardt T, Egle A, Greil R.
    Br J Haematol. 2014 Dec,167(5):716-8. doi: 10.1111/bjh.13049. Epub 2014 Jul 24.

    View this publication in the PUBMED database
  • 2014

    C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.

    Troppan KT, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, Greil R, Neumeister P, Pichler M.
    Br J Cancer. 2014 Jul 8,111(1):55-60. doi: 10.1038/bjc.2014.277. Epub 2014 May 29.

    View this publication in the PUBMED database
  • 2014

    Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.

    Melchardt T, Weiss L, Hufnagl C, Neureiter D, Kemmerling R, Morre P, Boekstegers A, Hopfinger G, Auberger J, Steinkirchner S, Pleyer L, Greil R, Egle A.
    Leuk Lymphoma. 2015 Feb,56(2):353-60. doi: 10.3109/10428194.2014.916798. Epub 2014 Jun 25.

    View this publication in the PUBMED database
  • 2014

    Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.

    Melchardt T, Magnes T, Weiss L, Grundbichler M, Strasser M, Hufnagl C, Moik M, Greil R, Egle A.
    BMC Complement Altern Med. 2014 Mar 30,14:115. doi: 10.1186/1472-6882-14-115.

    View this publication in the PUBMED database
  • 2014

    Human immunodeficiency virus type 2 infections in Austria.

    Taylor N, Kern JM, Prammer W, Lang A, Haas B, Gisinger M, Zangerle R, Egle A, Greil R, Oberkofler H, Eberle J.
    Wien Klin Wochenschr. 2014 Apr,126(7-8):212-6. doi: 10.1007/s00508-013-0493-1. Epub 2014 Jan 18.

    View this publication in the PUBMED database
  • 2014

    Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.

    Hopfinger G, Nösslinger T, Lang A, Linkesch W, Melchardt T, Weiss L, Egle A, Greil R.
    Ann Hematol. 2014 Mar,93(3):459-62. doi: 10.1007/s00277-014-2009-0. Epub 2014 Jan 18.

    View this publication in the PUBMED database
  • 2014

    Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma.

    Weiss L, Melchardt T, Habringer S, Boekstegers A, Hufnagl C, Neureiter D, Hopfinger G, Greil R, Egle A.
    Ann Oncol. 2014 Jan,25(1):171-6. doi: 10.1093/annonc/mdt481. Epub 2013 Dec 3.

    View this publication in the PUBMED database
  • 2014

    Pleural decortication of a marginal zone lymphoma.

    Melchardt T, Weiss L, Namberger K, Pretsch I, Hutter J, Rettenbacher L, Neureiter D, Troch M, Greil R, Egle A.
    Ann Hematol. 2014 Jul,93(7):1253-4. doi: 10.1007/s00277-013-1960-5. Epub 2013 Nov 22.

    View this publication in the PUBMED database
  • 2014

    "Old and new news in CLL: ""It""s the pathway, stupid!""."

    Egle, A,
    Blood. 2014 Aug 14,124(7):989-90. doi: 10.1182/blood-2014-05-574145.

    View this publication in the PUBMED database
  • 2014

    How does lenalidomide target the chronic lymphocytic leukemia microenvironment?

    Kater, AP, Tonino, SH, Egle, A, Ramsay, AG,
    Blood. 2014 Oct 2,124(14):2184-9. doi: 10.1182/blood-2014-05-578286. Epub 2014 Aug 26.

    View this publication in the PUBMED database
  • 2013

    Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results

    Vornamen sind ausgeschrieben-ändern? Alexander Egle, Michael Steurer, Franz Josef Gassner, Roland Geisberger, Thomas Melchardt, Lisa Pleyer, Lukas Weiss, Michael A. Fridrik, Josef Thaler, Alois Lang, Richard Greil,
    Blood (ASH Annual Meeting Abstracts). 2013. #4164:

    View this publication in the PUBMED database
  • 2013

    Blockade of the Potassium Channel KCa3.1 inhibits proliferation in Chronic Lymphocytic Leukemia

    Grossinger, EM, Weiss, L, Zierler, S, Hinterseer, E, Schmolzer, J, Asslaber, D, Hainzl, S, Egle, A, Pinon, JD, Hartmann, TN, Greil, R, Kerschbaum, HH
    ONKOLOGIE. 2013, 36: 191-192.

    View this publication in the PUBMED database
  • 2013

    The transcription factor IRF-4 is related to prognosis in Chronic Lymphocytic Leukemia (CLL) and involved in proliferation and survival

    Asslaber, D, Hofbauer, JP, Zaborsky, N, Kocher, T, Hartmann, TN, Greil, R, Egle, A
    ONKOLOGIE. 2013, 36: 222-223.

    View this publication in the PUBMED database
  • 2013

    Mimicking the microenvironment in chronic lymphocytic leukaemia - where does the journey go?

    Asslaber D, Grössinger EM, Girbl T, Hofbauer SW, Egle A, Weiss L, Greil R, Hartmann TN.
    Br J Haematol. 2013 Mar,160(5):711-4. doi: 10.1111/bjh.12151. Epub 2012 Dec 4.

    View this publication in the PUBMED database
  • 2013

    Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome.

    Melchardt T, Weiss L, Pleyer L, Steinkirchner S, Auberger J, Hopfinger G, Greil R, Egle A.
    Oncol Lett. 2013 Dec,6(6):1756-1758. Epub 2013 Oct 15.

    View this publication in the PUBMED database
  • 2013

    Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.

    Taylor N, Grabmeier-Pfistershammer K, Egle A, Greil R, Rieger A, Ledergerber B, Oberkofler H.
    PLoS One. 2013 Aug 30,8(8):e74024. doi: 10.1371/journal.pone.0074024. eCollection 2013.

    View this publication in the PUBMED database
  • 2013

    Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.

    Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, Steinkirchner S, Melchardt T, Mitrovic M, Girschikofsky M, Lang A, Krippl P, Sliwa T, Egle A, Linkesch W, Voskova D, Angermann H, Greil R.
    J Hematol Oncol. 2013 Apr 29,6:32. doi: 10.1186/1756-8722-6-32.

    View this publication in the PUBMED database
  • 2013

    Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient.

    Taylor N, Melchardt T, Grundbichler M, Strasser M, Egle A, Greil R.
    Ann Hematol. 2013 Jul,92(7):1001-2. doi: 10.1007/s00277-012-1659-z. Epub 2012 Dec 28.

    View this publication in the PUBMED database
  • 2013

    Viral infections and their management in patients with chronic lymphocytic leukemia.

    Melchardt T, Weiss L, Greil R, Egle A.
    Leuk Lymphoma. 2013 Aug,54(8):1602-13. doi: 10.3109/10428194.2012.755178. Epub 2013 Jan 3.

    View this publication in the PUBMED database
  • 2013

    What’s new in Hodgkin’s lymphoma: ASH 2012 and more

    Melchardt, T, Weiss, L, Greil, R, Egle, A,
    Magazine of European Medical Oncology. 2013, Volume 6, Issue 3: 193-196.

    View this publication in the PUBMED database
  • 2013

    Influence of Body Mass Index on survival in indolent and Mantle-cell Lymphomas: Analysis of the StiL1 trial

    Weiss, L, Melchardt, T, Egle, A, Hopfinger, G, Greil, R, Barth, J, Rummel, M
    ONKOLOGIE. 2013, 36: 31-32.

    View this publication in the PUBMED database
  • 2013

    [Autoimmune hemolysis accompanied by thrombopenia: consumption or myelodysplasia?].

    Melchardt, T, Weiss, L, Egle, A,
    Dtsch Med Wochenschr. 2013 Oct,138(41):2093-5. doi: 10.1055/s-0033-1349586. Epub 2013 Oct 1.

    View this publication in the PUBMED database
  • 2013

    Bid-ding for mercy: twisted killer in action.

    Egle A, Asslaber D, Villunger A, Pinon-Hofbauer J.
    Cell Death and Differentiation. 2013 Jul,20(7):847-9. doi: 10.1038/cdd.2013.40.

    View this publication in the PUBMED database
  • 2013

    p53 Efficiently Suppresses Tumor Development in the Complete Absence of Its Cell-Cycle Inhibitory and Proapoptotic Effectors p21, Puma, and Noxa.

    Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL, Janic A, Strasser A.
    Cell Rep. 2013 May 30,3(5):1339-45. doi: 10.1016/j.celrep.2013.04.012. Epub 2013 May 9.

    View this publication in the PUBMED database
  • 2013

    Protein Kinase C-?-Dependent Activation of NF-?B in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo.

    Lutzny G, Kocher T, Schmidt-Supprian M, Rudelius M, Klein-Hitpass L, Finch AJ, Dürig J, Wagner M, Haferlach C, Kohlmann A, Schnittger S, Seifert M, Wanninger S, Zaborsky N, Oostendorp R, Ruland J, Leitges M, Kuhnt T, Schäfer Y, Lampl B, Peschel C, Egle A, Ringshausen I.
    Cancer Cell. 2013 Jan 14,23(1):77-92. doi: 10.1016/j.ccr.2012.12.003.

    View this publication in the PUBMED database
  • 2012

    Lysine residue at position 22 of the AID protein regulates its class switch activity.

    Geisberger R, Huemer M, Gassner FJ, Zaborsky N, Egle A, Greil R.
    PLoS One. 2012,7(2):e30667. doi: 10.1371/journal.pone.0030667. Epub 2012 Feb 20.

    View this publication in the PUBMED database
  • 2012

    Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.

    Merkel O, Wacht N, Sifft E, Melchardt T, Hamacher F, Kocher T, Denk U, Hofbauer JP, Egle A, Scheideler M, Schlederer M, Steurer M, Kenner L, Greil R.
    Leukemia. 2012 Dec,26(12):2508-16. doi: 10.1038/leu.2012.147. Epub 2012 Jun 1.

    View this publication in the PUBMED database
  • 2012

    Treatment of Aggressive B-Cell Lymphoma in the Elderly: The Influence of SNPs Affecting Pharmacodynamics Is Different Compared to Younger Patient

    Thomas Melchardt, Lukas Weiss, Clemens Hufnagl, Daniel Neureiter, Ralf Kemmerling, Patrick Morre, Ann Boekstegers, Georg Hopfinger, Richard Greil, Alexander Egle,
    Blood (ASH Annual Meeting Abstracts) 2012. 2012. #1613:

    View this publication in the PUBMED database
  • 2012

    Feasibility of anthracycline based treatment in unselected elderly DLBCL patients

    Melchardt, T, Weiss, L, Hufnagl, C, Neureiter, D, Kemmerling, R, Hopfinger, G, Greil, R, Egle, A
    ONKOLOGIE. 2012, 35: 86-87.

    View this publication in the PUBMED database
  • 2012

    Complications of 5-azacytidine: Three cases of severe colitis in a single center cohort

    Melchardt, T, Weiss, L, Pleyer, L, Steinkirchner, S, Greil, R, Egle, A
    ONKOLOGIE. 2012, 35: 149-149.

    View this publication in the PUBMED database
  • 2012

    Treatment of Aggressive B-Cell Lymphoma in the Elderly: The Influence of SNPs Affecting Pharmacodynamics Is Different Compared to Younger Patient

    Melchardt, T, Weiss, L, Hufnagl, C, Neureiter, D, Kemmerling, R, Morre, P, Boekstegers, A, Hopfinger, G, Greil, R, Egle, A
    BLOOD. 2012, 120(21):

    View this publication in the PUBMED database
  • 2012

    AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)

    Gisslinger, H, Kralovics, R, Gisslinger, B, Lechner, D, Buxhofer-Ausch, V, Strecker, K, Gastl, G, Willenbacher, E, Greil, R, Egle, A, Melchardt, T, Burgstaller, S, Schloegl, E, Tarmann, FJ, Zoerer, M, Klade, C, Zahriychuk, O, Thaler, J
    BLOOD. 2012, 120(21):

    View this publication in the PUBMED database
  • 2012

    Upgraded Cobas TaqMan version 2: hidden consequences at cohort level

    Taylor, N, Grabmeier-Pfistershammer, K, Oberkofler, H, Egle, A, Rieger, A, Ledergerber, B
    J INT AIDS SOC. 2012, 15: 109-109.

    View this publication in the PUBMED database
  • 2011

    Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

    Gassner FJ, Weiss L, Geisberger R, Hofbauer JP, Egle A, Hartmann TN, Greil R, Tinhofer I.
    Cancer Immunol Immunother. 2011 Jan,60(1):75-85. doi: 10.1007/s00262-010-0920-3. Epub 2010 Sep 21.

    View this publication in the PUBMED database
  • 2011

    A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results

    Egle, A, Steurer, M, Gassner, F, Geisberger, R, Melchardt, T, Weiss, L, Fridrik, MA, Thaler, J, Lang, A, Greil, R
    BLOOD. 2011, 118(21): 135-136.

    View this publication in the PUBMED database
  • 2011

    Differential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells.

    Brachtl G, Sahakyan K, Denk U, Girbl T, Alinger B, Hofbauer SW, Neureiter D, Hofbauer JP, Egle A, Greil R, Hartmann TN.
    PLoS One. 2011,6(8):e23758. doi: 10.1371/journal.pone.0023758. Epub 2011 Aug 18.

    View this publication in the PUBMED database
  • 2011

    Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab.

    Weiss L, Melchardt T, Neureiter D, Kemmerling R, Moshir S, Pleyer L, Greil R, Egle A.
    J Clin Oncol. 2011 Aug 20,29(24):e696-8. doi: 10.1200/JCO.2011.35.8283. Epub 2011 Jul 5.

    View this publication in the PUBMED database
  • 2011

    Raltegravir in pregnancy: a case series presentation.

    Taylor N, Touzeau V, Geit M, Gisinger M, Egle A, Greil R, Rieger A, Zangerle R.
    Int J STD AIDS. 2011 Jun,22(6):358-60. doi: 10.1258/ijsa.2011.010469.

    View this publication in the PUBMED database
  • 2011

    Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.

    Hofbauer JP, Heyder C, Denk U, Kocher T, Holler C, Trapin D, Asslaber D, Tinhofer I, Greil R, Egle A.
    Leukemia. 2011 Sep,25(9):1452-8. doi: 10.1038/leu.2011.111. Epub 2011 May 24.

    View this publication in the PUBMED database
  • 2011

    Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.

    Weiss L, Melchardt T, Egle A, Grabmer C, Greil R, Tinhofer I.
    Cancer. 2011 May 15,117(10):2163-9. doi: 10.1002/cncr.25752. Epub 2010 Nov 18.

    View this publication in the PUBMED database
  • 2011

    Treatment of invasive aspergillosis in cancer patients.

    Auberger, J, Russ, G, Greil, R, Egle, A,
    memo - Magazine of European Medical Oncology. 2011, 4 (4): 266-272.

    View this publication in the PUBMED database
  • 2011

    Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group

    Pleyer, L, Stauder, R, Burgstaller, S, Schreder, M, Tinchon, C, Pfeilstocker, M, Steinkirchner, S, Melchardt, T, Mitrovic, M, Girschikofsky, M, Lang, A, Krippl, P, Egle, A, Sliwa, T, Linkesch, W, Fridrik, MA, Greil, R
    BLOOD. 2011, 118(21): 747-747.

    View this publication in the PUBMED database
  • 2011

    Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing Study

    Gisslinger, H, Kralovics, R, Schoder, R, Gisslinger, B, Buxhofer-Ausch, V, Strecker, K, Wolf, D, Willenbacher, E, Greil, R, Egle, A, Melchardt, T, Burgstaller, S, Tarmann, FJ, Wachter, C, Zahriycick, O, Thaler, J
    BLOOD. 2011, 118(21): 762-762.

    View this publication in the PUBMED database
  • 2011

    Tumor load reduction and prolongation of overall-survival by actinomycin D in a murine model of high-risk chronic lymphocytic leukemia

    Wacht, N, Sifft, E, Melchardt, T, Hamacher, F, Denk, U, Pinon-Hofbauer, J, Egle, A, Kocher, T, Steurer, M, Greil, R, Merkel, O
    ONKOLOGIE. 2011, 34: 141-141.

    View this publication in the PUBMED database
  • 2011

    CLL CELLS INDUCE CLONAL T CELL SKEWING AND SUBSETSHIFTING IN THE MURINE TCL1 TRANSGENIC CHRONIC LYMPHOCYTIC LEUKEMIA MODEL

    Egle, A, Pinon-Hofbauer, J, Heyder, C, Denk, U, Kocher, T, Holler, C, Trapin, D, Asslaber, D, Tinhofer, I, Greil, R
    ANN ONCOL. 2011, 22: 144-144.

    View this publication in the PUBMED database
  • 2011

    Clonal Diversity of the T Cell Repertoire Predicts Disease Progression in Chronic Lymphocytic Leukaemia

    Holler, C, Zaborsky, N, Hofbauer, JP, Kocher, T, Trapin, D, Asslaber, D, Greil, R, Egle, A
    BLOOD. 2011, 118(21): 365-365.

    View this publication in the PUBMED database
  • 2011

    Clinical aspects of 2009 pandemic influenza A (H1N1) virus infection in Austria.

    Poeppl, W, Hell, M, Herkner, H, Stoiser, B, Fritsche, G, Schurz-Bamieh, N, Poeppl, G, Gattringer, R, Jones, N, Maass, M, Egle, A, Burgmann, H,
    Infection. 2011 Aug,39(4):341-52. doi: 10.1007/s15010-011-0121-9. Epub 2011 May 5.

    View this publication in the PUBMED database
  • 2010

    MicroRNAs as biomarkers for the diagnosis and prognosis of human cancer.

    Asslaber D, Pinon Hofbauer J, Greil R, Egle A.
    Journal of Nucleic Acids Investigations. 2010, Dec 1, 1(1): 76-80.

    View this publication in the PUBMED database
  • 2010

    An uncommon cause of anaemia: Sheehan's syndrome.

    Melchardt T, Namberger K, Weiss L, Egle A, Faber V, Greil R.
    Wien Klin Wochenschr. 2010 Dec,122(23-24):717-9. doi: 10.1007/s00508-010-1480-4. Epub 2010 Dec 7.

    View this publication in the PUBMED database
  • 2010

    Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.

    Merkel O, Asslaber D, Piñón JD, Egle A, Greil R.
    Cell Cycle. 2010 Jul 15,9(14):2764-8. Epub 2010 Jul 3.

    View this publication in the PUBMED database
  • 2010

    microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.

    Asslaber D, Piñón JD, Seyfried I, Desch P, Stöcher M, Tinhofer I, Egle A, Merkel O, Greil R.
    Blood. 2010 May 27,115(21):4191-7. doi: 10.1182/blood-2009-07-234823. Epub 2010 Jan 20.

    View this publication in the PUBMED database
  • 2010

    Enzastaurin kills human CLL cells regardless of clinical risk profile, but fails to prolong life in a murine CLL model

    Kocher, T, Pinon, HJ, Holler, C, Denk, U, Greil, R, Egle, A
    ONKOLOGIE. 2010, 33: 40-40.

    View this publication in the PUBMED database
  • 2010

    Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study

    Egle, A, Weiss, L, Melchardt, T, Gunsilius, E, Petzer, AL, Fridrik, M, Lang, A, Krieger, O, Thaler, J, Greil, R
    BLOOD. 2010, 116(21): 593-594.

    View this publication in the PUBMED database
  • 2010

    Deletion of Puma and p21(Waf1) In Mice Deactivates p53-Induced Cell Death and Cell Cycle Arrest, but Protects Mice From Irradiation-Induced Lymphomagenesis by a Mechanism Involving Hemopoietic Stem Cell Quiescence

    Hofbauer, JP, Holler, C, Denk, U, Asslaber, D, Fastner, G, Labi, V, Villunger, A, Greil, R, Egle, A
    BLOOD. 2010, 116(21): 45-46.

    View this publication in the PUBMED database
  • 2010

    Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation.

    Labi V, Erlacher M, Krumschnabel G, Manzl C, Tzankov A, Pinon J, Egle A, Villunger A.
    Genes Dev. 2010 Aug 1,24(15):1602-7. doi: 10.1101/gad.1940210.

    View this publication in the PUBMED database
  • 2010

    Riding the 2-edged sword.

    Egle A.
    Blood. 2010 Jun 3,115(22):4325-6. doi: 10.1182/blood-2010-03-272211.

    View this publication in the PUBMED database
  • 2009

    Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.

    Hartmann TN, Pleyer L, Desch P, Egle A, Greil R.
    Discov Med. 2009 Oct,8(42):157-64.

    View this publication in the PUBMED database
  • 2009

    Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

    Pleyer L, Egle A, Hartmann TN, Greil R.
    Nat Rev Clin Oncol. 2009 Jul,6(7):405-18. doi: 10.1038/nrclinonc.2009.72. Epub 2009 Jun 2.

    View this publication in the PUBMED database
  • 2009

    Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals.

    Taylor N, Schmid I, Egle A, Greil R, Patsch W, Oberkofler H.
    Antivir Ther. 2009,14(8):1189-93. doi: 10.3851/IMP1427.

    View this publication in the PUBMED database
  • 2009

    PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.

    Holler C, Piñón JD, Denk U, Heyder C, Hofbauer S, Greil R, Egle A.
    Blood. 2009 Mar 19,113(12):2791-4. doi: 10.1182/blood-2008-06-160713. Epub 2009 Jan 23.

    View this publication in the PUBMED database
  • 2009

    The REVLIRIT CLL5 AGMT Study - a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis

    Egle, A, Steurer, M, Melchardt, T, Stoll, M, Greil, R
    BLOOD. 2009, 114(22): 1341-1342.

    View this publication in the PUBMED database
  • 2009

    The Inverse Correlation of Regulatory T Cells and Time to Initial Treatment in Chronic Lymphocytic B-Cell Leukemia

    Weiss, L, Melchardt, T, Grabmer, C, Egle, A, Tinhofer, I, Greil, R
    BLOOD. 2009, 114(22): 510-510.

    View this publication in the PUBMED database
  • 2009

    FINAL RESULTS OF ORAL FLUDARABINE WITH CONCOMITANT SUBCUTANEOUS ALEMTUZUMAB IN RELAPSED/REFRACTORY B-CHRONIC LYMPHOCYTIC LEUKAEMIA (B-CLL): THE FLUSALEM STUDY

    Egle, A, Melchardt, T, Pleyer, L, Tinhofer, I, Lang, A, Keil, F, Thaler, J, Gunsilius, E, Fridrik, M, Greil, R
    HAEMATOL-HEMATOL J. 2009, 94: 140-140.

    View this publication in the PUBMED database
  • 2008

    Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study.

    Egle, A, Weiss, L, Gassner, F, Russ, G, Pleyer, L, Gunsilius, E, Tinhofer, I, Thaler, J, Petzer, AL, Greil, R
    BLOOD. 2008, 112(11): 1089-1089.

    View this publication in the PUBMED database
  • 2008

    T Cell Dynamics during the Pretumor and Tumor Phase in the Murine Tcll Transgenic Chronic Lymphocytic Leukemia Model

    Egle, A, Pinon, JD, Heyder, C, Holler, C, Denk, U, Tinhofer, I, Greil, R
    BLOOD. 2008, 112(11): 1078-1078.

    View this publication in the PUBMED database
  • 2008

    Bim and Bmf in tissue homeostasis and malignant disease.

    Piñon JD, Labi V, Egle A, Villunger A.
    Oncogene. 2008 Dec,27 Suppl 1:S41-52. doi: 10.1038/onc.2009.42.

    View this publication in the PUBMED database
  • 2007

    Planned first efficacy and safety analysis of de-intensified induction with fludarabine, cyclophosphamide plus rituximab (FCR) followed by fludarabine plus rituximab (FR) and remission maintenance therapy with rituximab in previously untreated B-chronic lymphocytic leukemia (B-CLL): The chairos study

    Egle, A, Weiss, L, Russ, G, Thoedtmann, R, Pleyer, L, Gastl, G, Thaler, J, Petzer, A, Tinhofer, I, Greil, R
    BLOOD. 2007, 110(11): 609A-609A.

    View this publication in the PUBMED database
  • 2006

    The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial.

    Tinhofer I, Steurer M, Leitinger G, Rumpold H, Egle A, Erdel M, Greil R.
    Haematologica. 2006 Sep,91(9):1291-3.

    View this publication in the PUBMED database
  • 2006

    Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia.

    Tinhofer I, Rubenzer G, Holler C, Hofstaetter E, Stoecher M, Egle A, Steurer M, Greil R.
    Blood. 2006 Nov 1,108(9):2950-6. Epub 2006 Jul 6.

    View this publication in the PUBMED database
  • 2006

    Planned first safety and efficacy analysis of oral fludarabine combined with subcutaneous alemtuzumab in 2(nd) line therapy of B-chronic lymphocytic leukaemia (B-CLL): The FLUSALEM study.

    Egle, A, Tinhofer, I, Russ, G, Rass, C, Greil, R
    BLOOD. 2006, 108(11): 336B-336B.

    View this publication in the PUBMED database
  • 2005

    Expression levels of CD38 in tumor cells and T-cells are of prognostic value in B-CLL

    Tinhofer, I, Rubenzer, G, Egle, A, Greil, R
    BLOOD. 2005, 106(11): 347A-347A.

    View this publication in the PUBMED database
  • 2001

    Stepping up treatment with Rituxan (R) (rituximab, Mabthera (R)) for CLL patients with advanced stage of disease relapsing after or refractory to conventional chemotherapy.

    Greil, R, Steurer, M, Egle, A, Stauder, R, Anether, G, Ulmer, L, Tinhofer, I, Gastl, G
    BLOOD. 2001, 98(11): 289B-290B.

    View this publication in the PUBMED database
  • 2000

    Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques.

    Marschitz I, Tinhofer I, Hittmair A, Egle A, Kos M, Greil R.
    Am J Clin Pathol. 2000 Feb,113(2):219-29.

    View this publication in the PUBMED database
  • 2000

    Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.

    Tinhofer I, Marschitz I, Henn T, Egle A, Greil R.
    Blood. 2000 Jan 15,95(2):610-8.

    View this publication in the PUBMED database
  • 1998

    On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.

    Greil R, Egle A, Villunger A.
    Leuk Lymphoma. 1998 Nov,31(5-6):477-90.

    View this publication in the PUBMED database
  • 1998

    Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity.

    Villunger A, Egle A, Kos M, Egle D, Tinhofer I, Henn T, Uberall F, Maly K, Greil R.
    Br J Haematol. 1998 Sep,102(4):1069-80.

    View this publication in the PUBMED database
  • 1998

    Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.

    Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, Greil R.
    Blood. 1998 Jun 1,91(11):4273-81.

    View this publication in the PUBMED database
  • 1998

    Inversion of CD4(+)/CD8(+) ratio in B chronic lymphocytic leukemia correlates with differential sensitivity of CD4(+) and CD8(+) T lymphocytes to the killing efficacy of Fas (APO-1/CD95) ligand(+) tumor cells.

    Tinhofer, I, Marschitz, I, Kos, M, Henn, T, Egle, A, Villunger, A, Greil, R
    BLOOD. 1998, 92(10): 271B-271B.

    View this publication in the PUBMED database
  • 1997

    Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.

    Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R.
    Cancer Res. 1997 Aug 15,57(16):3331-4.

    View this publication in the PUBMED database
  • 1997

    The interleukin 1beta-converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells.

    Geley S, Hartmann BL, Kapelari K, Egle A, Villunger A, Heidacher D, Greil R, Auer B, Kofler R.
    FEBS Lett. 1997 Jan 27,402(1):36-40.

    View this publication in the PUBMED database
  • 1997

    Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.

    Villunger A, Egle A, Marschitz I, Kos M, Böck G, Ludwig H, Geley S, Kofler R, Greil R.
    Blood. 1997 Jul 1,90(1):12-20.

    View this publication in the PUBMED database
  • 1997

    Expression of Apo-1/Fas (CD95), Bcl-2 Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.

    Egle A, Villunger A, Marschitz I, Kos M, Hittmair A, Lukas P, Grünewald K, Greil R.
    Br J Haematol. 1997 May,97(2):418-28.

    View this publication in the PUBMED database
  • 1997

    Fas (Apo-1/CD95) - Ligand expression on neoplastic plasma cells and its role for the expansion of the neoplastic clone.

    Greil, R, Villunger, A, Egle, A, Marschitz, L, Kos, M, Bock, G, Ludwig, H, Geley, S, Kofler, R
    BLOOD. 1997, 90(10): 1578-1578.

    View this publication in the PUBMED database
  • 1996

    Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.

    Egle A, Villunger A, Kos M, Böck G, Gruber J, Auer B, Greil R.
    Eur J Immunol. 1996 Dec,26(12):3119-26.

    View this publication in the PUBMED database
  • 1996

    IL-10 serum levels in B-cell chronic lymphocytic leukaemia.

    Egle A, Marschitz I, Posch B, Herold M, Greil R.
    Br J Haematol. 1996 Jul,94(1):211-2.

    View this publication in the PUBMED database
  • 1996

    2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).

    Gruber J, Geisen F, Sgonc R, Egle A, Villunger A, Boeck G, Konwalinka G, Greil R.
    Stem Cells. 1996 May,14(3):351-62.

    View this publication in the PUBMED database
  • 1996

    Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.

    Villunger A, Egle A, Kos M, Hittmair A, Maly K, Greil R.
    Int J Cancer. 1996 Feb 8,65(4):498-505.

    View this publication in the PUBMED database
  • 1995

    Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response.

    Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jäger G, LeMevel A, Najman A, Silingardi V, Spriano M, van Hoof A, Ehmer B.
    Blood. 1995 Dec 15,86(12):4446-53.

    View this publication in the PUBMED database


Tel.: +43 57255-57700


Fax: +43 57255-25991

E-Mail: a.egle@salk.at

 

Zuständigkeit:

 

Infektiologische Einheit

Infektiologische Ambulanz

Hämatologische Ambulanz

HIV Ambulanz

Stammzellen-Labor

LIMCR, Gruppe: Murine Lymphommodelle